Trial Profile

A global Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AJ201 in ambulatory individuals with symptomatic Spinal and Bulbar Muscular Atrophy (SBMA)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 13 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Mar 2026 New trial record
04 Mar 2026 According to AnnJi Pharmaceutical media release, enrollment in this trial is anticipated to commence in late 2026.
04 Mar 2026 According to AnnJi Pharmaceutical media release, the preliminary design of this phase 3 trial was shared by Dr. Christopher Grunseich, MD, the Principal Investigator, in a scientific abstract during the 2026 International Patient and Scientific Conference hosted by the Kennedy's Disease Association (KDA) held February 27 - March 2.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com